Aspire Bariatrics Inc.
Fighting morbid obesity with stomach aspiration
This article was originally published in Start Up
An ideal minimally invasive bariatric technology should be safe, easily implantable, suitable as a permanent therapy, and allow patients to eat a normal diet. Aspire Bariatrics Inc. thinks its solution fits the bill. With the AspireAssist Aspiration Therapy System, patients have control over their weight loss as they are able, about 20 minutes after a meal, to drain a portion of their stomach contents through an endoscopically implanted tube, thus reducing the number of calories absorbed by the body.
You may also be interested in...
Several emerging medtechs are developing products and procedures that are less invasive, less expensive, easier to deliver, and more easily reversible than bariatric surgery. With support from investors and the FDA, these firms are poised to reap big rewards in the massive, undermet obesity market.
Nearly half of the world’s adult population will be overweight or obese by 2030 and obesity is tied to more than 40 diseases. Enterprising companies are heeding the call with increasingly less invasive weight loss devices, while an amenable regulatory environment means the marketplace will welcome some of these innovations in 2015.
The Fight Against Fat: Start-Ups Look To Serve A Vast Market With Minimally Invasive Bariatric Devices
Start-ups with an array of compelling devices are seeking to provide alternatives to invasive gastric bypass surgery and laparoscopic gastric banding for the millions of morbidly and moderately obese patients – but which ones will make it through the evolving FDA clinical process? In this issue we profile three young companies that hope to succeed: Aspire Bariatrics, EndoSphere, and Vibrynt.